OOS, OOT, OOC, and OOSC - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

OOS, OOT, OOC, and OOSC
Current GMPs demand full understandng of out-of-control concepts. This article contains bonus material.


Pharmaceutical Technology
Volume 35, Issue 10, pp. 46-47


Lynn D. Torbeck
The pharmaceutical industry is not immune to rampant proliferation of acronyms. To alleviate confusion about being out-of-control (OOC), this column proposes concepts and definitions for the industry.

No plant manager wants to hear the words, "Your process is out-of-control." The process was probably designed, developed, nursed, nurtured, fine-tuned, tested, and coddled until it met the definition of a validated process (1). Now, someone who was never involved in process development declares it is as OOC. Not a welcome message and it begs the question, "out-of-control for what?" Modifiers and definitions are needed.

There are several ways that the process can be described as OOC. There could be equipment failures or changes in the raw materials used. The process could be financially OOC (i.e., losing money), or out-of-regulatory-control with cGMP violations. Perhaps the operators are creating excessive deviations and confusion by not following the standard operating procedures because of a dysfunctional work culture; managerial malfeasance has resulted in the demise of several companies in the past. If we say it is OOC, we are obligated to specify how.

The most notorious lack of control is being out-of-specification (OOS, 2). An OOS situation exists when a reportable result collected at a single point in time exceeds a predetermined specification (3).

This event precipitates a cascade of activity as described in the OOS guidance. This has been discussed extensively for years and is well understood by the industry.


ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Looking forward 10 years from now, what do you think will be the most significant change to drug development and manufacturing?
Fuller adoption of quality by design principles
Greater adoption of continuous manufacturing
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
The rise of biologic-based drugs in commercial product portfolios and pipelines
Greater adoption of the preferred provider model in outsourcing
Fuller adoption of quality by design principles
22%
Greater adoption of continuous manufacturing
7%
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
35%
The rise of biologic-based drugs in commercial product portfolios and pipelines
30%
Greater adoption of the preferred provider model in outsourcing
7%
View Results
Jim MillerOutsourcing OutlookJim Miller Channeling Steve Jobs
Patricia Van ArnumIngredients InsiderPatricia Van ArnumSeeking Chemocatalytic and Biocatalytic Solutions
Nathan JessopIndustry InsiderNathan Jessop Taxing Times for French Pharma
Lynn D. TorbeckStatistical Solutions Lynn D. TorbeckRepresentative Sampling
Report on Recent and Upcoming Single-Use Meetings
ICH Q11 Reaches Harmonization, Implementation is Next
Digital Signatures Growing as a Result of Part 11
Single-Cell Genomics Advancing Molecular Biology
Putting FDA’s “Process Validation” Guidance into Action
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here